The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) for efficacy on 2020-06-29. This approval, designated BLA 125514 S-84, was sponsored by Merck Sharp Dohme.
Background
Pembrolizumab (Keytruda) is an established therapeutic agent. This supplemental approval indicates an expansion of its approved uses or patient population based on demonstrated efficacy. The specific new indication or patient population for this supplemental approval was not detailed in the provided source information.
What this means
This supplemental FDA approval for Keytruda (pembrolizumab) signifies an expansion of its approved indications or patient population. Such approvals broaden the scope of patients who can benefit from the drug, offering new treatment options. Clinicians and researchers will need to consult the full FDA approval document for specific details regarding the expanded use.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 125514 S-84 for Keytruda (pembrolizumab) was posted on 2020-06-29 on accessdata.fda.gov.